financetom
Business
financetom
/
Business
/
Philip Morris lifts annual profit forecast on nicotine pouch demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Philip Morris lifts annual profit forecast on nicotine pouch demand
Jul 23, 2024 5:29 AM

(Reuters) - Philip Morris International ( PM ) raised its annual adjusted profit forecast on Tuesday, owing to steady demand for its Zyn nicotine pouches and higher prices of its cigarettes.

Its shares were up 2% in premarket trading after the company also beat expectations for second-quarter revenue.

Zyn nicotine pouches have so far been at the forefront of the company's effort to claim a larger chunk of the demand for alternatives to traditional cigarettes in the United States.

Zyn shipment volumes grew 50.3% in the second quarter, compared with the same period last year, despite supply constraints and a nationwide suspension of the product's online sales. That followed a nearly 80% rise in the prior quarter.

Philip Morris ( PM ) expects an adjusted annual per-share profit, excluding currency, of between $6.67 and $6.79, compared with its earlier forecast of $6.55 to $6.67 per share.

The company also expects annual nicotine pouch shipment volumes in the U.S. of 560 million to 580 million cans, up from its earlier expectation of 560 million cans.

Like its peers, Philip Morris ( PM ) has been raising cigarette prices to offset volume declines amid stricter regulation and greater awareness of health risks, which have led to falling demand in some markets.

It has also been working to ramp up production of Zyn, which it acquired through a purchase of Swedish Match in 2022, to meet demand in the U.S.

The company is facing some resistance from anti-smoking groups ahead of the trial launch of its heated tobacco product, IQOS, in the country.

Overall shipment volume for its heated tobacco business rose 13.1% compared to a year ago, following a 20.9% rise in the prior quarter.

The company reported second-quarter revenue of $9.47 billion, beating analysts' average estimate of $9.18 billion, according to LSEG data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved